175 related articles for article (PubMed ID: 30084010)
1. Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
Wang H; Li Y; Lv N; Li Y; Wang L; Yu L
Ann Hematol; 2018 Nov; 97(11):2025-2038. PubMed ID: 30084010
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Silencing of
Lee P; Yim R; Miu KK; Fung SH; Liao JJ; Wang Z; Li J; Yung Y; Chu HT; Yip PK; Lee E; Tse E; Kwong YL; Gill H
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628480
[TBL] [Abstract][Full Text] [Related]
3. Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
Gill H
Br J Haematol; 2024 May; 204(5):1577-1578. PubMed ID: 38563073
[TBL] [Abstract][Full Text] [Related]
4. Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress.
Venugopal S; Shallis RM; Zeidan AM
Expert Rev Anticancer Ther; 2023; 23(9):903-911. PubMed ID: 37470508
[TBL] [Abstract][Full Text] [Related]
5. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.
Campillo-Marcos I; Casado-Pelaez M; Davalos V; Ferrer G; Mata C; Mereu E; Roué G; Valcárcel D; Molero A; Zamora L; Xicoy B; Palomo L; Acha P; Manzanares A; Tobiasson M; Hellström-Lindberg E; Solé F; Esteller M
Cancer Res Commun; 2024 Feb; 4(2):365-377. PubMed ID: 38300528
[TBL] [Abstract][Full Text] [Related]
6. Gene Expression and DNA Methylation Profiling Suggest Potential Biomarkers for Azacitidine Resistance in Myelodysplastic Syndrome.
Kim DY; Shin DY; Oh S; Kim I; Kim EJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731939
[TBL] [Abstract][Full Text] [Related]
7. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.
Pereira MP; Herrity E; Kim DDH
Ann Hematol; 2024 Apr; 103(4):1049-1067. PubMed ID: 37770618
[TBL] [Abstract][Full Text] [Related]
8. CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine.
Karantanos T; Teodorescu P; Arvanitis M; Perkins B; Jain T; DeZern AE; Dalton WB; Christodoulou I; Paun BC; Varadhan R; Esteb C; Rajkhowa T; Bonifant C; Gondek LP; Levis MJ; Yegnasubramanian S; Ghiaur G; Jones RJ
Haematologica; 2023 Jul; 108(7):1886-1899. PubMed ID: 36519323
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors.
Ye C; Jiang N; Zheng J; Zhang S; Zhang J; Zhou J
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189066. PubMed ID: 38163523
[TBL] [Abstract][Full Text] [Related]
10. Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia.
Sorrentino VG; Thota S; Gonzalez EA; Rameshwar P; Chang VT; Etchegaray JP
Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358067
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Garcia JS; Flamand Y; Penter L; Keng M; Tomlinson BK; Mendez LM; Koller P; Cullen N; Arihara Y; Pfaff K; Wolff JO; Brunner AM; Galinsky I; Bashey A; Antin JH; Cutler C; Ho V; Jonas BA; Luskin MR; Wadleigh M; Winer ES; Savell A; Leonard R; Robertson T; Davids MS; Streicher H; Rodig SJ; Ritz J; Wu CJ; DeAngelo DJ; Neuberg D; Stone RM; Soiffer RJ
Blood; 2023 Apr; 141(15):1884-1888. PubMed ID: 36332187
[TBL] [Abstract][Full Text] [Related]
12. [Current state of treatment for myelodysplastic syndromes].
Ichikawa M
Rinsho Ketsueki; 2023; 64(9):988-997. PubMed ID: 37793875
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.
Leone G; D'Alò F; Zardo G; Voso MT; Nervi C
Curr Med Chem; 2008; 15(13):1274-87. PubMed ID: 18537607
[TBL] [Abstract][Full Text] [Related]
14. Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes.
Lee SE; Wang F; Grefe M; Trujillo-Ocampo A; Ruiz-Vasquez W; Takahashi K; Abbas HA; Borges P; Antunes DA; Al-Atrash G; Daver N; Molldrem JJ; Futreal A; Garcia-Manero G; Im JS
Clin Cancer Res; 2023 May; 29(10):1938-1951. PubMed ID: 36988276
[TBL] [Abstract][Full Text] [Related]
15. [Molecular mechanism of DNA hypomethylating agents in myeloid tumors].
Yabushita T; Kitamura T; Goyama S
Rinsho Ketsueki; 2024; 65(4):209-221. PubMed ID: 38684430
[No Abstract] [Full Text] [Related]
16. What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach.
Awada H; Gurnari C; Xie Z; Bewersdorf JP; Zeidan AM
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190176
[TBL] [Abstract][Full Text] [Related]
17. DNA methyltransferase inhibitor exposure-response: Challenges and opportunities.
Kagan AB; Garrison DA; Anders NM; Webster JA; Baker SD; Yegnasubramanian S; Rudek MA
Clin Transl Sci; 2023 Aug; 16(8):1309-1322. PubMed ID: 37345219
[TBL] [Abstract][Full Text] [Related]
18. miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms.
Mayer MC; Berg JL; Perfler B; Hatzl S; Herzog SA; Bachmaier G; Berghold A; Reinisch A; Wölfler A; Sill H; Zebisch A
Ann Hematol; 2021 Nov; 100(11):2845-2847. PubMed ID: 34291333
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.
Kubasch AS; Peterlin P; Cluzeau T; Götze KS; Sockel K; Teipel R; Jentzsch M; Attalah H; Sebert M; Chermat F; Gloaguen S; Puttrich M; Cross M; Schneider M; Kayser S; Schipp D; Giagounidis A; Tirado-Gonzalez I; Descot A; van de Loosdrecht A; Weigert A; Metzeler KH; Fenaux P; Medyouf H; Platzbecker U; Ades L
Leukemia; 2023 Nov; 37(11):2309-2313. PubMed ID: 37735558
[No Abstract] [Full Text] [Related]
20. Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target.
Wang YH; Lin CC; Gurashi K; Wingelhofer B; Amaral FMR; Yao CY; Hsieh HT; Liu MC; Hou HA; Chou WC; Batta K; Wiseman DH; Tien HF
Leukemia; 2023 Dec; 37(12):2507-2511. PubMed ID: 37919605
[No Abstract] [Full Text] [Related]
[Next] [New Search]
